currents -  Tariffs to 25% and Now the Virus ! (36672 views) Notify me whenever anyone posts in this discussion.Subscribe
From: gunter DelphiPlus Member Icon 5/15/20 9:00 AM 
To: All  (171 of 235) 
 2076.171 in reply to 2076.170 

 Reply   Options 

From: Paul (SNOTZALOT) DelphiPlus Member Icon5/20/20 8:01 AM 
To: gunter DelphiPlus Member Icon   (172 of 235) 
 2076.172 in reply to 2076.171 

Disclaimer: I am long INO

PLYMOUTH MEETING, Pa., May 20, 2020 /PRNewswire/ -- INOVIO (NASDAQ:INO) today announced the publication of the preclinical study data for IN0-4800, its COVID-19 DNA vaccine, demonstrating robust neutralizing antibody and T cell immune responses against coronavirus SARS-CoV-2. The study was published in the peer-reviewed journal Nature Communications titled, "Immunogenicity of a DNA vaccine candidate for COVID-19" by INOVIO scientists and collaborators from The Wistar Institute, the University of Texas, Public Health England, Fudan University, and Advaccine.

Dr. Kate Broderick, INOVIO's Senior Vice President of R&D and the Team Lead for COVID-19 vaccine development, said, "These positive preclinical results from our COVID-19 DNA vaccine (INO-4800) not only highlight the potency of our DNA medicines platform, but also build on our previously reported positive Phase 1/2a data from our vaccine against the coronavirus that causes MERS, which demonstrated near-100% seroconversion and neutralization from a similarly designed vaccine INO-4700. The potent neutralizing antibody and T cell immune responses generated in multiple animal models are supportive of our currently on-going INO-4800 clinical trials."

INO-4800 targets the major surface antigen Spike protein of SARS-CoV-2 virus, which causes COVID-19 disease. The studies demonstrated that vaccination with INO-4800 generated robust binding and neutralizing antibody as well as T cell responses in mice and guinea pigs. Importantly, the authors demonstrated virus neutralizing activity using three separate neutralization assays testing the vaccine's ability to generate antibodies which can block virus infection by: 1) an assay using live SARS-CoV-2 viruses; 2) an assay using a pseudo-virus assay, where another virus displays the SARS-CoV-2 Spike protein; and, 3) a novel high-throughput surrogate neutralization assay measuring the ability of INO-4800-induced antibodies to block SARS-CoV-2 Spike binding to the host ACE2 receptor. Study authors also detected these antibodies in the lungs of the vaccinated animals which could be important in providing protection from SARS-CoV-2. In addition, high levels of Spike-specific T cell responses were observed with INO-4800 vaccination, which could be important in mediating protection from the virus infection. Collectively, this preclinical dataset demonstrates that INO-4800 is a promising COVID-19 vaccine candidate against this emerging disease threat.

  • Edited May 20, 2020 8:02 am  by  Paul (SNOTZALOT)

From: gunter DelphiPlus Member Icon 5/21/20 10:24 AM 
To: Paul (SNOTZALOT) DelphiPlus Member Icon  (173 of 235) 
 2076.173 in reply to 2076.172 


From: Paul (SNOTZALOT) DelphiPlus Member Icon5/21/20 12:12 PM 
To: gunter DelphiPlus Member Icon   (174 of 235) 
 2076.174 in reply to 2076.173 

If there was no unemployment compensation, these lazy people would get off the sofa and find  a job, right?


From: gunter DelphiPlus Member Icon 5/21/20 6:46 PM 
To: Paul (SNOTZALOT) DelphiPlus Member Icon  (175 of 235) 
 2076.175 in reply to 2076.174 

Right. There are many tremendous jobs out there. There are more jobs than ever before my administration, probably in the history of the world. You'll hear more soon about the investigation looking into Obama. You'll be surprised or may not !


From: gunter DelphiPlus Member Icon 5/25/20 10:12 AM 
To: All  (176 of 235) 
 2076.176 in reply to 2076.139 

Monkeys and elephants missing tourist handouts and now even the rats are starving!


From: gunter DelphiPlus Member Icon 5/27/20 7:04 PM 
To: All  (177 of 235) 
 2076.177 in reply to 2076.176 


From: gunter DelphiPlus Member Icon 5/28/20 8:53 AM 
To: All  (178 of 235) 
 2076.178 in reply to 2076.177 


From: gunter DelphiPlus Member Icon 5/28/20 9:10 AM 
To: All  (179 of 235) 
 2076.179 in reply to 2076.178 


From: gunter DelphiPlus Member Icon 6/4/20 9:31 AM 
To: All  (180 of 235) 
 2076.180 in reply to 2076.179 

Navigate this discussion: 1-10 11-20 21-30 ... 151-160 161-170 171-180 181-190 191-200 ... 211-220 221-230 231-235
Adjust text size:

Welcome, guest! Get more out of Delphi Forums by logging in.

New to Delphi Forums? You can log in with your Facebook, Twitter, or Google account or use the New Member Login option and log in with any email address.

Home | Help | Forums | Chat | Blogs | Privacy Policy | Terms of Service
© Delphi Forums LLC All rights reserved.